Dong-A Pharmaceutical Co.,Ltd. (동아제약(주))
KOSPI Stock Code: 000640 | DART Corp Code: 00116824
English names are as registered with DART and may differ from the Korean legal name. Use corp_code, stock_code, or business registration number to identify a company.
| English name (as registered with DART) | Dong-A Pharmaceutical Co.,Ltd. |
|---|---|
| Korean legal name | 동아제약(주) |
| Alternate names | 동아제약 |
| Market | KOSPI |
| Stock Code | 000640 |
| DART Corp Code | 00116824 |
| CEO | 김민영 |
| Business Registration No. | 2048100130 |
| Corporate Registration No. | 1101110017990 |
| Established Date | 1949-08-09 |
| Fiscal Month | 12 |
| KSIC Industry Code | 64992 |
| Address (KO) | 서울특별시 동대문구 천호대로 64 |
| Homepage | https://www.donga.co.kr/ |
| source_url | https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260318001307 |
| verified_at | 2026-11-01T02:16:03.464Z |
Annual Financial Summary (KRW)
Fiscal Year: 2025 | Basis: CFS (Consolidated) | Currency: KRW | Filing Source: https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260318001307
| Account | FY2025 (Current) | FY2024 (Prior) |
|---|---|---|
| Revenue (매출액) | KRW 1,429,766,810,735 | KRW 1,333,229,636,666 |
| Operating Income (영업이익) | KRW 97,772,974,663 | KRW 82,094,664,924 |
| Net Income (당기순이익) | KRW 91,466,489,869 | KRW 57,573,399,359 |
| Total Assets (자산총계) | KRW 2,079,304,723,754 | KRW 2,030,483,787,016 |
| Total Liabilities (부채총계) | KRW 927,773,911,607 | KRW 966,546,316,740 |
| Total Equity (자본총계) | KRW 1,151,530,812,147 | KRW 1,063,937,470,276 |
Recent DART Filings (Last 90 Days, up to 20)
| Filed Date | Receipt No. | English Title | Korean Title | Filer |
|---|---|---|---|---|
2026-10-30 | 20261030800944 | Material Business Matters Related to Investment Decisions(Subsidiary's material business matters) (제2형 당뇨병 치료 복합제 슈가엠파정 국내 품목허가 승인) | 투자판단관련주요경영사항(자회사의 주요경영사항) (제2형 당뇨병 치료 복합제 슈가엠파정 국내 품목허가 승인) | 동아제약 |
2026-10-27 | 20261027800214 | Organization of Investor Relations Event | 기업설명회(IR)개최(안내공시) | 동아제약 |
2026-10-27 | 20261027800177 | Report on Business Performance according to Consolidated Financial Statements (Fair Disclosure) | 연결재무제표기준영업(잠정)실적(공정공시) | 동아제약 |
2026-10-22 | 20261022800425 | Organization of Investor Relations Event | 기업설명회(IR)개최(안내공시) | 동아제약 |
2026-10-22 | 20261022800420 | Prior Notice on Disclosure of Final Earnings | 결산실적공시예고(안내공시) | 동아제약 |
2026-10-16 | 20261016800364 | Conclusion of Single Sales Contract or Supply Contract(Subsidiary's material business matters) | 단일판매ㆍ공급계약체결(자회사의 주요경영사항) | 동아제약 |
2026-10-08 | 20261008000287 | Report on status of specific securities, etc. owned by executives and major shareholders | 임원ㆍ주요주주특정증권등소유상황보고서 | 홍민아 |
2026-10-08 | 20261008000284 | Report on status of specific securities, etc. owned by executives and major shareholders | 임원ㆍ주요주주특정증권등소유상황보고서 | 조진욱 |
2026-10-08 | 20261008000283 | Report on status of specific securities, etc. owned by executives and major shareholders | 임원ㆍ주요주주특정증권등소유상황보고서 | 정민 |
2026-10-08 | 20261008000276 | Report on status of specific securities, etc. owned by executives and major shareholders | 임원ㆍ주요주주특정증권등소유상황보고서 | 이남용 |
2026-10-08 | 20261008000275 | Report on status of specific securities, etc. owned by executives and major shareholders | 임원ㆍ주요주주특정증권등소유상황보고서 | 윤춘희 |
2026-10-08 | 20261008000270 | Report on status of specific securities, etc. owned by executives and major shareholders | 임원ㆍ주요주주특정증권등소유상황보고서 | 신남수 |
2026-10-08 | 20261008000269 | Report on status of specific securities, etc. owned by executives and major shareholders | 임원ㆍ주요주주특정증권등소유상황보고서 | 송인식 |
2026-10-08 | 20261008000268 | Report on status of specific securities, etc. owned by executives and major shareholders | 임원ㆍ주요주주특정증권등소유상황보고서 | 차태웅 |
2026-10-08 | 20261008000266 | Report on status of specific securities, etc. owned by executives and major shareholders | 임원ㆍ주요주주특정증권등소유상황보고서 | 오종원 |
2026-10-08 | 20261008000263 | Report on status of specific securities, etc. owned by executives and major shareholders | 임원ㆍ주요주주특정증권등소유상황보고서 | 김용운 |
2026-10-08 | 20261008000260 | Report on status of specific securities, etc. owned by executives and major shareholders | 임원ㆍ주요주주특정증권등소유상황보고서 | 강보성 |
2026-10-08 | 20261008000256 | Report on status of specific securities, etc. owned by executives and major shareholders | 임원ㆍ주요주주특정증권등소유상황보고서 | 백상환 |
2026-10-08 | 20261008800299 | Report on Shares Change of Largest Shareholders | 최대주주등소유주식변동신고서 | 동아제약 |
2026-10-02 | 20261002800881 | Inclusion of Subsidiary in Holding Company | 지주회사의자회사편입 | 동아제약 |
Source & Disclaimer
source_url: https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260318001307 | verified_at: 2026-11-01T02:16:03.464Z
Data from Korea's Financial Supervisory Service (DART) and National Tax Service. FSS does not guarantee accuracy or completeness. Figures in KRW as filed. Not investment advice. English names are as registered with DART and may differ from the Korean legal name. Use corp_code, stock_code, or business registration number to identify a company.